Subha Vogeti

Discovery of Acyl Ureas as Highly Selective Small Molecule CSF1R Kinase Inhibitors.

Stacie L. Bulfer, Michael D. Kaufman, B. Le Bourdonnec, 2022, Bioorganic & medicinal chemistry letters.

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).

Stacie L. Bulfer, Michael D. Kaufman, B. Le Bourdonnec, 2022, Bioorganic & medicinal chemistry letters.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

P. Hipskind, D. Clawson, D. Manglicmot, 2015, Journal of medicinal chemistry.

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Stacie L. Bulfer, O. Rosen, M. Heinrich, 2019, Cancer cell.

Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.

J. Kozarich, J. Rosenblum, G. Sharma, 2016, Biochemistry.

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015, Cancer cell.

Inhibition of RAF Isoforms and Active Dimers by LY 3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Graphical

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015 .

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

L. Stewart, Michael D. Kaufman, D. Flynn, 2015, Molecular Cancer Therapeutics.

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Michael D. Kaufman, L. Davis, R. Ruiz-Soto, 2021, Molecular Cancer Therapeutics.